| OR | Oestrogen receptor |
|---|
| designer oestrogen | An engineered drug that possesses some, but not all, of the actions of oestrogen. Designer oestrogens are selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 Dec 1998) |
|---|
| designer drugs | Drugs designed and synthesised, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are mptp (a reverse ester of meperidine), mda (3,4-methylenedioxyamphetamine), and mdma (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines. (12 Dec 1998) |
|---|---|
| catechol oestrogen | Any 2-hydroxylated derivative of an oestrogen; they, with their methylated derivatives, can account for up to one-half of all excreted oestrogen metabolites. (05 Mar 2000) |
| conjugated oestrogen | <pharmacology> An amorphous preparation of naturally occurring, water-soluble, conjugated forms of mixed oestrogen's obtained from the urine of pregnant mares; the principal oestrogen present is sodium estrone sulfate; suitable for parenteral, oral, and topical administration, and used in conditions responsive to oestrogen therapy. (05 Mar 2000) |
| selective oestrogen-receptor modulator | <pharmacology> An antioestrogen which possesses some, but not all, of the actions of oestrogen. For example, raloxifene (evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. Acronym: SERM (17 Jul 2002) |
| oestrogen | <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones. In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo. Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders. (18 Nov 1997) |
| oestrogen antagonist | <pharmacology> A drug or compound which inhibit or antagonise the action or biosynthesis of oestrogen. Tamoxifen also has agonist or stimulatory actions as well as blocking effects. There are also selective oestrogen-receptor modulators (SERMs). For example, raloxifene (trade name Evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus. (12 May 2002) |
| oestrogen receptor | <cell biology> Cytoplasmic proteins that bind oestrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of oestrogen receptors in breast cancer patients has become clinically important and determines the likelihood of response to anti-oestrogen therapy with tamoxifen. (17 Jul 2002) |
| oestrogen replacement therapy | <endocrinology, gynaecology> The use of oestrogenic substances in postmenopausal or other oestrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, dyspareunia, and progressive development of osteoporosis. (12 Dec 1998) |
| testosterone-oestrogen-binding globulin | A glycoprotein migrating as a beta-globulin. Its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. The protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. Changes in its concentration significantly affect the ratio of unbound (biologically active) testosterone to estradiol in plasma. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|